FINWIRES · TerminalLIVE
FINWIRES

Stifel Downgrades Fulcrum Therapeutics to Hold From Buy, Adjusts PT to $3 From $25

By

Fulcrum Therapeutics (FULC) has an average rating of Hold and mean price target of $9.22, according to analysts polled by FactSet.

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

Related Articles

Research

Cantor Fitzgerald Downgrades Fulcrum Therapeutics to Neutral From Overweight

Fulcrum Therapeutics (FULC) has an average rating of Hold and mean price target of $9.22, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

$FULC
Research

Jefferies Downgrades Abivax SA to Hold From Buy, Adjusts PT to $90 From $160

$ABVX
Research

JPMorgan Downgrades Sociedad Quimica y Minera de Chile S.A. to Neutral From Overweight, Adjusts PT to $100 From $94

$SQM